Results 81 to 90 of about 3,797 (192)

Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Genetics and Molecular Biology
Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued.
Luciana Santos Pessoa, Luãnna Liebscher Vidal, Emmerson C.B. da Costa, Celina Monteiro Abreu, Rodrigo Delvecchio da Cunha, Ana Luiza Chaves Valadão, André Felipe dos Santos, Amilcar Tanuri   +7 more
doaj   +1 more source

Fototoxiciteit na de inname van simeprevir voor de behandeling van hepatitis C

, 2016
Simeprevir is een nieuw geneesmiddel dat gebruikt wordt in de curatieve behandeling van hepatitis C, genotype 1 en 4. Het wordt toegediend in combinatie met peginterferon-alfa en ribavirine of in een interferonvrije combinatie met sofosbuvir.
Hoorens, Isabelle, Van Vlierberghe, Hans, Desmidt, Florence, Thoen, Hendrik, Geerts, Anja, Verhelst, Xavier   +5 more
core  

Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms

, 2017
Up till now the role of simeprevir plasma concentrations has not been described in treated patients affected by chronic hepatitis C and with dermatological side-effects.
D'AVOLIO, ANTONIO, CUSATO, JESSICA, CARCIERI, CHIARA, Cariti, Giuseppe, ARIAUDO, ALESSANDRA, BOGLIONE, Lucio, FAVATA, FABIO, MORNESE PINNA, SIMONE, DE NICOLO', AMEDEO, DI PERRI, Giovanni   +9 more
core   +1 more source

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

PLoS ONE, 2017
BackgroundIntracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR).
Valeria Cento, Thi Huyen Tram Nguyen, Domenico Di Carlo, Elisa Biliotti, Laura Gianserra, Ilaria Lenci, Daniele Di Paolo, Vincenza Calvaruso, Elisabetta Teti, Maddalena Cerrone, Dante Romagnoli, Michela Melis, Elena Danieli, Barbara Menzaghi, Ennio Polilli, Massimo Siciliano, Laura Ambra Nicolini, Antonio Di Biagio, Carlo Federico Magni, Matteo Bolis, Francesco Paolo Antonucci, Velia Chiara Di Maio, Roberta Alfieri, Loredana Sarmati, Paolo Casalino, Sergio Bernardini, Valeria Micheli, Giuliano Rizzardini, Giustino Parruti, Tiziana Quirino, Massimo Puoti, Sergio Babudieri, Antonella D'Arminio Monforte, Massimo Andreoni, Antonio Craxì, Mario Angelico, Caterina Pasquazzi, Gloria Taliani, Jeremie Guedj, Carlo Federico Perno, Francesca Ceccherini-Silberstein   +40 more
doaj   +1 more source

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

ClinicoEconomics and Outcomes Research, 2015
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V   +4 more
doaj  

Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens

The Egyptian Journal of Internal Medicine, 2019
Background The recommended reliance on 12 weeks posttreatment sustained virological response (SVR12) instead of SVR24 was validated for treatment evaluation. Aim Judging claimed concordance between SVR12 and SVR24.
Maha M Elsabaawy, Khalid Gameel, Heba Eldemerdash, Talaat Zakareia, Mahmoud Eltahawy, Marry Albert, Marwa Fekry, Enas Ouda, Helmy Elshazly, Ashraf Eljaky   +9 more
doaj   +1 more source

Pooled risk ratio of sustained virological response at weeks 12 and 24 after the end of treatment between simeprevir plus pegylated interferon-ribavirin and pegylated interferon-ribavirin.

, 2018
Pooled risk ratio of sustained virological response at weeks 12 and 24 after the end of treatment between simeprevir plus pegylated interferon-ribavirin and pegylated interferon-ribavirin.
Thunyarat Anothaisintawee (840641), Yot Teerawattananon (180232), Ammarin Thakkinstian (840643), Thanthima Suwanthawornkul (840640), Abhasnee Sobhonslidsuk (840642)   +4 more
core   +1 more source

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Revista do Instituto de Medicina Tropical de São Paulo, 2018
Due to the severity of chronic hepatitis C, there are multiple factors that can negatively affect the quality of life of infected patients. The aim of this study was to evaluate changes in the health-related quality of life (HRQoL) in patients under ...
Fabiane Mateus Siqueira, Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Roberto Pontarolo   +3 more
doaj   +1 more source

Comparison of crystal structures of NS3 protease with and without the Q80K variant complexing with TMC-435350 (Simeprevir).

, 2016
Similar changes in structure are seen in both genotype 1a and genotype 6a. NS3 protease is shown as light blue ribbon. Yellow structure represents simeprevir (TMC-435350). Residues pictured are as follows: gray (Q80), blue (R155) and red (D168).
Charles Wang (242565), Xiaoping Tang (234051), Chuanyi Ning (464950), Kali Zhou (3163539), Joseph D. Tucker (197659), Weiping Cai (299830), Fengyu Hu (415120), Yun Lan (819172), Zhiwei Liang (509222)   +8 more
core   +1 more source

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj